Details of the Drug
General Information of Drug (ID: DMEL8XU)
Drug Name |
5-(pyridin-4-yl)-1,3,4-thiadiazole-2(3H)-thione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
13581-25-4; 5-(pyridin-4-yl)-1,3,4-thiadiazole-2-thiol; CHEMBL596214; 5-(4-pyridyl)-1,3,4-thiadiazole-2-thiol; 5-(pyridin-4-yl)-1,3,4-thiadiazole-2(3H)-thione; 5-pyridin-4-yl-1,3,4-thiadiazole-2-thiol; 5-mercapto-2-(pyridin-4-yl)-1,3,4-thiadiazole; 1,3,4-Thiadiazole-2(3H)-thione, 5-(4-pyridinyl)-; AC1NRXV6; 5-pyridin-4-yl-3H-1,3,4-thiadiazole-2-thione; SCHEMBL969939; CTK0F4035; DTXSID70415420; MolPort-002-738-405; BDBM50304604; ZINC13532584; STK328652; AKOS030229631; AKOS005174322; MCULE-1265725983; KB-243965; R9200; ST45106367
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 195.3 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||